Dyadic International (DYAI) AI Stock Analysis

• Market Cap: $36.41M
• Dividend Yield: N/A
• Average Volume (3M): 43.99K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.09
• Revenue Growth: 20.58%
• EPS Growth: 15.90%
• Country: US
• Employees: 6
• Sector: Healthcare
• Sector Strength: 64
• Industry: Biotechnology
• EPS (TTM): -0.20
• Shares Outstanding: 30,090,660
• 10 Day Avg. Volume: 17,213
• 30 Day Avg. Volume: 43,988
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 12.40
• Price to Cash Flow (P/CF): -51.90
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $6.00
• Price Target Upside: 395.87% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

Dyadic International's overall score reflects significant financial challenges, notably ongoing losses and negative cash flows. While strategic partnerships and revenue growth are positive, they are offset by high leverage and operational inefficiencies. The stock's technical indicators suggest weak momentum, and its valuation remains unattractive due to unprofitability. The earnings call provides some optimism about future growth, but near-term challenges persist.

Dyadic International Business Overview & Revenue Model

Company Description

Dyadic International (DYAI) is a biotechnology company that focuses on developing and commercializing biopharmaceuticals and bio-based products using its proprietary C1 gene expression platform. This platform is designed to enable the efficient and cost-effective production of biologic products, including vaccines, antibodies, and enzymes, across various industries such as healthcare, agriculture, and industrial enzymes.

How the Company Makes Money

Dyadic International generates revenue through licensing its C1 gene expression technology to pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments, and royalties based on the commercial success of products developed using the C1 platform. The company also engages in research and development collaborations, where it provides its expertise and technology in exchange for funding. Additionally, Dyadic may generate revenue through the sale of its proprietary enzymes and other bio-based products developed using its platform.

Dyadic International Financial Statement Overview

Summary

Dyadic International faces significant financial challenges, including negative net income and cash flows, despite some revenue growth. The company's high leverage and operational inefficiencies pose risks, although maintaining liquidity through cash reserves is a positive aspect.

Income Statement

Dyadic International has shown some revenue growth over the years, with a 20.6% increase from 2023 to 2024. However, the company has consistently reported negative net income, leading to negative net profit margins. The EBIT and EBITDA margins are also negative, indicating ongoing operational challenges.

Balance Sheet

The company's debt-to-equity ratio has increased significantly in 2024, indicating higher leverage and potential financial risk. The equity ratio has decreased over the years, reflecting a lower proportion of equity financing. However, the company maintains a reasonable amount of cash and short-term investments, providing some liquidity cushion.

Cash Flow

Operating cash flows have been negative, reflecting challenges in generating cash from operations. Free cash flow has also remained negative, though there was a notable decrease in the cash outflow in 2024 compared to previous years. The operating cash flow to net income ratio indicates a gap between reported earnings and cash generation, which may concern investors.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
3.50M	2.90M	2.93M	2.40M	1.60M
	Gross Profit
2.30M	922.96K	807.11K	459.39K	176.99K
	EBIT
-5.90M	-8.23M	-10.12M	-14.73M	-10.03M
	EBITDA
-5.90M	-8.19M	-10.07M	-13.07M	-10.19M
	Net Income Common Stockholders
-5.81M	-6.80M	-9.37M	-12.92M	-9.33M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
9.26M	7.26M	12.64M	20.26M	29.09M
	Total Assets
9.93M	8.22M	13.71M	21.30M	30.07M
	Total Debt
5.07M	136.93K	0.00	0.00	0.00
	Net Debt
-1.44M	-6.38M	-5.79M	-15.75M	-20.64M
	Total Liabilities
7.46M	2.34M	2.63M	2.91M	1.63M
	Stockholders Equity
2.47M	5.88M	11.09M	18.39M	28.45M
Cash Flow		Free Cash Flow
-3.97M	-6.73M	-8.08M	-11.28M	-6.57M
	Operating Cash Flow
-3.97M	-6.73M	-8.08M	-11.28M	-6.57M
	Investing Cash Flow
-1.88M	7.45M	-2.37M	5.22M	22.12M
	Financing Cash Flow
5.85M	0.00	543.59K	1.23M	255.47K

Dyadic International Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.21
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DYAI, the sentiment is Negative. The current price of 1.21 is below the 20-day moving average (MA) of 1.27, below the 50-day MA of 1.38, and below the 200-day MA of 1.39, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 39.43 is Neutral, neither overbought nor oversold. The STOCH value of 35.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DYAI.

Dyadic International Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SPRO	53 Neutral	$40.93M	10.83	-89.62%	―	-71.68%	-397.61%
Sector *	51 Neutral	$5.20B	3.26	-40.34%	2.93%	17.68%	1.94%
DYAI	46 Neutral	$36.41M	―	-139.16%	―	20.58%	15.90%
BRNS	34 Underperform	$30.39M	―	-38.49%	―	1773.18%	19.16%
ANTX	34 Underperform	$39.58M	―	-49.69%	―	―	38.98%
IBIO	29 Underperform	$6.91M	―	-123.28%	―	650.00%	89.72%

Dyadic International Corporate Events

Dyadic International Secures $4.5M for Vaccine Development

On March 20, 2025, Dyadic International announced a $4.5 million funding award from CEPI to accelerate the development of protein-based vaccines using its C1 fungus technology. The initiative aims to reduce vaccine development timelines significantly, potentially enabling vaccines to enter Phase 1 trials in just 35 days compared to the traditional four to six months. This approach could also lower production costs and increase accessibility, particularly in regions with less established manufacturing infrastructure, aligning with the global 100 Days Mission to expedite vaccine readiness against pandemic threats.